TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Smoking patient: daily tobacco consumption.~* Patient with cancer requiring surgical treatment (breast cancer, digestive cancer, gynecological).~* Patient wishing to quit smoking.~* Fagerström \> 3.~* Patient has valid health insurance~* Information and agreement of the patient to participate in the longitudinal cohort.~* Signing of specific informed consent for patients in groups 1 to 4 before any study-related intervention.~* Person able to speak, read and understand French.~Exclusion Criteria:~* Patient not receiving surgical treatment.~* Refusal to participate in the longitudinal cohort study.~* Pregnant or likely to be pregnant or nursing patient.~* Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian~* disability to undergo the medical follow-up of the trial for geographical, social or psychological reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1:Nicotine Replacement Therapy (NRT) (Type: ACTIVE_COMPARATOR): Patients enrolled in group 1 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study
- Group 2:Motivational Interviewing (MI) (Type: EXPERIMENTAL): Patients enrolled in group 2 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization
- Group 3:Cognitive Behavioural Therapy (CBT) (Type: EXPERIMENTAL): Patients enrolled in group 3 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization and 6 sessions of CBT after Motivational Interviewing up to 6 months after
- Group 4: Hypnotherapy (Type: EXPERIMENTAL): Patients enrolled in group 4 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization and about 3 sessions of hypnotherapy up to 6 months after

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Advanced MRI in AAA

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥ 18 years of age)~* Abdominal aortic aneurysm with a maximal aneurysm diameter of at least 30 mm~Exclusion Criteria:~* Contra-indications for MRI~* Severely reduced renal function (eGFR \< 30)~* Previous allergic reaction to intravenous contrast agents~* Suprarenal AAA~* Pararenal AAA~* Previous aneurysm repair~* Inflammatory aneurysm~* Mycotic or other infectious aneurysm~* Vasculitis~* Connective tissue disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optimization phase (Type: None): The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.
- Study phase (Type: None): This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA.~These twenty patients will be scanned twice, with an interval of 1 week ± 5 days.~The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of diffuse large B-cell\* or peripheral T-cell non-Hodgkin's lymphoma by REAL/WHO classification, including the following:~  * All morphological and clinical variants~ * All Ann Arbor stages NOTE: \*Presence of a small cell, indolent lymphoma component in the bone marrow biopsy is allowed~* No Burkitt-like lymphoma~* Previously untreated disease~* No cerebral or meningeal involvement~* At least 1 measurable target lesion at least 1.1 cm by the Cheson criteria~PATIENT CHARACTERISTICS:~Age~* 70 and over~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3 (unless related to bone marrow infiltration)~Hepatic~* Bilirubin less than 1.8 mg/dL\*~* AST or ALT less than 2.5 times upper limit of normal (ULN)\*~* Alkaline phosphatase less than 4 times ULN\* NOTE: \*Values above these thresholds are allowed only if related to non-Hodgkin's lymphoma~Renal~* Creatinine clearance at least 50 mL/min~Cardiovascular~* LVEF at least 50%~Other~* HIV negative~* No history of concurrent severe disease that would preclude study treatment~* No other prior or concurrent malignancy except adequately treated basal cell skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid malignancy with no evidence of disease for at least 5 years prior to study entry~* No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No concurrent participation in another investigational drug study~* No other concurrent antineoplastic agents

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tissue Procurement Substudy for Participants in Study CP-MGA271-01

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Qualified, by meeting all inclusion and exclusion criteria, for participation in Study CP-MGA271-01.~* Must have provided informed consent to participate in Study CP-MGA271-01.~* Must have accessible tumors (generally speaking, metastatic deposits involving skin, subcutaneous tissue, or peripheral lymph node whose excision, punch biopsy, or core needle biopsy would not require general anaesthesia or the invasion of a body cavity).~* Willing to undergo two minor surgical procedures with no expectation of personal benefit~* Have provided Informed Consent for this substudy as indicated by a signature on an approved consent document obtained from the patient or his/her legally authorized representative~Exclusion Criteria:~* Any medical condition that would contraindicate the use of local or locoregional anaesthesia, or conscious sedation for the intended minor surgical procedure.~* Any medical condition (eg. skin disease or bleeding diathesis) that would hinder wound healing following a minor surgical procedure.~* Dementia or altered mental status that would preclude understanding and rendering of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MGA271 (Type: EXPERIMENTAL): MGA271 (administered in main study CP-MGA271-01)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Post-menopausal women that have incidentally found adrenal adenomas with benign appearing characteristics on imaging (\<4 cm, non-contrast CT \<10 HU and/or lipid rich and benign appearing on MRI)~* Absence of anti-anabolic clinical features of overt Cushing's signs (proximal muscle weakness, \>three ecchymoses, hyperpigmented striae) and 2 of 3 of the following:~  * Elevated 24 hr urine free cortisol (UFC) above the upper limit of normal (\>50 mcg/24 hours) in at least two complete 24-hour tests and/or~ * Late night salivary cortisol more than upper limit of normal in at least two tests and/or~ * an abnormal dexamethasone suppression defined as post 1mg dexamethasone suppression test serum cortisol concentration of \>1.8 mcg/ml~* Clinic status of cessation of menses for 12 mo in a previously cycling woman and reflecting complete or nearly complete permanent cessation of ovarian function and fertility (26).~* Patients with osteoporosis that are not receiving treatment with either antiresorptive medications (bisphosphonates, denosumab) or anabolic agents (teriparitide, abaloparatide or romosozumab)~Exclusion Criteria:

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GnRH antagonist (Elagolix) (Type: EXPERIMENTAL): Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Variants and Chemotherapy-induced Abnormal Thermal Sensation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 20 years old~* Pathological stage I\~IV for ovarian cancer, stage II\~IV for endometrial cancer, or stage III for colorectal cancer.~* Scheduled to receive adjuvant Paclitaxel/Carboplatin for ovarian or endometrial cancer, or mFOLFOX6 for colorectal cancer.~* Patient willing to provide blood sample for research purposes.~* Ability of the patient to provide informed consent.~Exclusion Criteria:~* Prior treatment with neurotoxic chemotherapy, such as oxaliplatin, cisplatin, carboplatin, taxanes or vinca alkaloids.~* Receiving chemotherapy within 6 months.~* A family history of a genetic or familial neuropathy~* Poor compliance

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Patients with endometrial or ovarian cancer (Type: None): None
- Patients with colorectal cancer (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 confirmed positive by a microbiologic test.~* Mild COVID-19 - no or mild pneumonia~* EITHER~  1. Uncomplicated acute appendicitis without a fecalith OR~ 2. Acute cholecystitis - by TG18/TG13 diagnostic criteria where definite diagnosis requires one item in A + one item in B + C A. Local signs of inflammation etc.~  <!-- -->~  1. Murphy's sign~ 2. RUQ mass/pain/tenderness B. Systemic signs of inflammation etc.~  <!-- -->~  1. Fever~ 2. elevated CRP~ 3. elevated WBC count C. Imaging findings characteristic of acute cholecystitis~Exclusion Criteria:~* Active pregnancy~* COVID-19 severe disease that would be a contraindication to operative intervention at the discretion of the attending surgeon supported by the following, none of which are individually required or are a strict exclusion criterion as some of these could be attributed or exacerbated by the underlying surgical problem:~  1. Persistent dyspnea~ 2. Persistent respiratory frequency \>30/min~ 3. Persistent blood oxygen saturation \<93%~ 4. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio \<300~ 5. Lung infiltrates \>50%~* COVID-19 critical disease - respiratory failure, shock, or multiorgan dysfunction~* The surgeon expects increased operative complexity - high risk of conversion to open or prolonged procedure~* Unable or unwilling to consent or fulfill study procedures - need to complete 90 day follow-up by telephone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Operative management (Type: ACTIVE_COMPARATOR): Treatment with surgery
- Non-operative management (Type: ACTIVE_COMPARATOR): Treatment with antibiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed diagnosis of breast cancer with documented progressive disease~  * Metastatic disease~* Measurable disease as defined by RECIST criteria or evaluable disease~* Must have received at least one prior chemotherapy regimen for metastatic breast cancer~  * Patients refusing all other chemotherapy for breast cancer may enroll without prior treatment~* Patients with HER2-overexpression disease must have been previously treated with trastuzumab (Herceptin®)~* Patients with stable brain metastases are eligible~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Life expectancy ≥ 12 weeks~* Absolute Neutrophil Count (ANC) ≥ 1,000/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)~* Total bilirubin ≤ 1.5 times ULN~* Able to take oral medications and maintain hydration~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after treatment~* No severe concurrent illness including, but not limited to, any of the following:~  * Congestive heart failure~ * Significant cardiac disease~ * Uncontrolled hypertension~* Must be able to read and speak English~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 2 weeks since prior treatment, including chemotherapy, hormonal therapy, trastuzumab (Herceptin®), or other targeted therapies~* Prior bevacizumab allowed if discontinued for any reason other than toxicity~* No potent inducers or inhibitors of CYP3A4 enzymes that effect the metabolism of sunitinib malate~* No prior sunitinib malate~* No other concurrent investigational therapy~* No concurrent radiotherapy~* Concurrent bisphosphonates allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Sunitinib, Cyclophosphamide, and Methotrexate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Acute Lymphoblastic Leukemia (ALL)~* BCR-ABL positive positive by PCR (central Lab)~* No previous treatment for ALL except for corticoids and cyclophosphamide less than 600 mg/m2~* Must be able to swallow tablets~* Lab results within normal limits (Potassium, Calcium, Magnesio, Phosphorus, Transaminases, Alkaline Phosphatase, Bilirrubine, Amylase, Lypase)~Exclusion Criteria:~* Heart disease~* Interval QTc Fridericia \> 480 msec~* Coumadin use~* Pregnancy~* PS = 4~* Previous medical history of etilism or/and pancreatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- nilotinib (Type: EXPERIMENTAL): single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18~* Histological or cytological diagnosis of adeno- or undifferentiated non-small cell carcinoma of pancreas.~* Considered to be unresectable based on following: extensive peri-pancreatic lymph node involvement, encasement or occlusion of the SMV or SMV/portal vein confluence, direct involvement of SMA, coeliac axis, inferior vena cava or aorta.~* Performance status 0-2~* No evidence of metastatic disease as determined by CT scan/ other investigations~* Adequate bone marrow function with platelets\>100\^9/l; WBC\>3x10\^9/l;neutrophils\> 1.5x10\^9/l~* Serum bilirubin ,1.5 x ULN and transaminases \< 2.5 x ULN~* Calculated/measured GFR \>50ml/min~* No concurrent uncontrolled medical condition~* No active malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix over the last 10 years~* Life expectancy \> 3months~* Adequate contraceptive precautions~* Informed written consent~Exclusion Criteria:~* medical or psychiatric conditions that compromise the patient's ability to give informed consent~* Presence of met. disease~* Concurrent uncontrolled medical conditions~* Any previous chemo/RT or any investigational treatment for advanced pancreatic cancer.~* Adjuvant chemo + fluoropyrimidine or gemcitabine within 12months of trial entry~* Adjuvant RT with/without chemo for pancreatic cancer.~* Pregnancy/breast feeding~* Patients with known malabsorption syndromes ro a lack of physical treatment of the upper GI tract.~* Patients with a known hypersensitivity to 5-FU or with a DPD deficiency.~* Clinically significant CVD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): UFT/LV + RT
- Group 2 (Type: ACTIVE_COMPARATOR): UFT/LV + RT + Cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed biliary tract or gallbladder cancer that have relapsed or are refractory after one prior gemcitabine-based chemotherapy regimen for advanced biliary cancer~* Evaluable disease~* ECOG PS ≤ 2~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Treatment with more than one prior chemotherapy regimen~* Known, uncontrolled CNS metastases~* Baseline peripheral neuropathy ≥ grade 2.~* Significant circulatory disorders in the past 6 months~* Concomitant use of phosphodiesterase inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPI-1620 & Docetaxel (Type: EXPERIMENTAL): Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* UnitedHealthcare member~* confirmed COVID-19 positive~* located in an area where Bamlanivimab (LY3819253) is available for infusion~Exclusion Criteria:~* current (from first symptom report) hospitalization for COVID-19~* prior administration of Bamlanivimab or other COVID-19 therapies~* previous COVID-19 diagnosis~* prior receipt of a COVID-19 vaccine~* not authorized for patient use per the EUA

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Participants with COVID-19 (Type: EXPERIMENTAL): Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval